- Home
- RYET vs CRDF Comparison
RYET vs CRDF Comparison
Compare RYET & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYET
- CRDF
- Stock Information
- Founded
- RYET 2012
- CRDF 1999
- Country
- RYET China
- CRDF United States
- Employees
- RYET N/A
- CRDF N/A
- Industry
- RYET
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RYET
- CRDF Health Care
- Exchange
- RYET NYSE
- CRDF Nasdaq
- Market Cap
- RYET 206.2M
- CRDF 169.6M
- IPO Year
- RYET 2025
- CRDF N/A
- Fundamental
- Price
- RYET $12.58
- CRDF $3.35
- Analyst Decision
- RYET
- CRDF Strong Buy
- Analyst Count
- RYET 0
- CRDF 4
- Target Price
- RYET N/A
- CRDF $12.25
- AVG Volume (30 Days)
- RYET 1.3M
- CRDF 839.8K
- Earning Date
- RYET 01-01-0001
- CRDF 05-08-2025
- Dividend Yield
- RYET N/A
- CRDF N/A
- EPS Growth
- RYET N/A
- CRDF N/A
- EPS
- RYET N/A
- CRDF N/A
- Revenue
- RYET $6,989,985.00
- CRDF $587,000.00
- Revenue This Year
- RYET N/A
- CRDF N/A
- Revenue Next Year
- RYET N/A
- CRDF N/A
- P/E Ratio
- RYET N/A
- CRDF N/A
- Revenue Growth
- RYET N/A
- CRDF N/A
- 52 Week Low
- RYET $2.68
- CRDF $2.01
- 52 Week High
- RYET $15.30
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- RYET N/A
- CRDF 63.72
- Support Level
- RYET N/A
- CRDF $2.81
- Resistance Level
- RYET N/A
- CRDF $3.43
- Average True Range (ATR)
- RYET 0.00
- CRDF 0.19
- MACD
- RYET 0.00
- CRDF 0.08
- Stochastic Oscillator
- RYET 0.00
- CRDF 85.54
About RYET RUANYUN EDAI TECHNOLOGY INC
Ruanyun Edai Technology Inc is primarily engaged in providing online academic exercise question banks with A.I. capabilities, online classes and homework, and on-demand lectures and evaluations that cover all K-12 subject fields and grade levels.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.